Niga-ichigoside F1, an ursolic acid-type pentacyclic triterpenoid, possesses various pharmacological properties, including anti-tumor, anti-inflammatory, and antinociceptive potentials. However, its function and underlying mechanism in ulcerative colitis (UC) remain unknown. Hence, this study aimed to explore the effect of Niga-ichigoside F1 on dextran sulfate sodium (DSS)-induced colitis. The predictive results of network pharmacology identified 311 common targets of Niga-ichigoside F1 and ulcerative colitis. The 4 highest-scoring genes were screened by the BottleNeck method and they were, signal transducer and activator of transcription 3 (STAT3), tumor necrosis factor (TNF), protein kinase B gamma (AKT3), and phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta (PIK3CB). KEGG pathway analysis indicated that Niga-ichigoside F1 probably exerted a protective effect on UC through the nuclear factor-kappa B (NF-κB) pathways. Molecular docking results showed that Niga-ichigoside F1 had a high affinity for nuclear factor-kappa B-inhibitor of nuclear factor-kappa B (NF-κB-IκB) complex, with the lowest binding energy. Furthermore, our results in vivo showed that Niga-ichigoside F1 alleviated weight loss, colon shortening, disease activity index (DAI), and histological scoring in DSS-induced colitis mice. Moreover, Niga-ichigoside F1 decreased the levels of inflammatory cytokines tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and interleukin-8 (IL-8) and the expression of oxidative stress markers nitric oxide (NO), myeloperoxidase (MPO), and malonaldehyde (MDA) to mitigate inflammation and intestinal damage. Western blotting results evidenced that Niga-ichigoside F1 intervention significantly regulated the NF-κB pathway. In conclusion, this study highlighted the potential of Niga-ichigoside F1 in ameliorating colitis, indicating its potential application as a functional food.